C4 Therapeutics

CCCC · NASDAQ

$3.16+$0.27 (+9.34%)TodayMarket closed · Oct 20, 7:45 PM ET

Prev close $2.89

CCCC analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $13.60 (+330.4% upside)

Low: $7.07
Now: $3.16
High: $31.50

Upgrades and downgrades

The latest rating actions, newest first

CCCC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Oct 9, 2026	Initiates	Overweight	$10.00	48%
Evercore ISI Group	Jun 1, 2026	Maintains	Outperform	$7.00 → $12.00	42%
Barclays	Feb 27, 2026	Maintains	Overweight	$5.00 → $7.00	46%
Brookline Capital	Feb 23, 2026	Maintains	Buy	$20.00 → $30.00	67%
Barclays	Dec 17, 2025	Maintains	Overweight	$10.00 → $5.00	46%
TD Cowen	Dec 2, 2025	Initiates	Buy	—	49%

The case for and against

Updated Mar 13, 2026

Bull case

C4 Therapeutics is positioned favorably due to the promising efficacy of its lead candidate, cemsidomide, which demonstrated a 34% overall response rate (ORR) in heavily pre-treated relapsed/refractory multiple myeloma patients, outperforming a comparable competitor's ORR of 25% in a similar patient cohort. The company’s targeted approach reduces the supportive care burden associated with treatments, potentially enhancing patient quality of life and treatment adherence. Moreover, preclinical data indicates that cemsidomide can activate T-cells and improve cancer cell killing when combined with other therapies, underscoring its potential to transform treatment protocols in oncology.

Bear case

C4 Therapeutics Inc faces several challenges that contribute to a negative outlook, primarily influenced by decreased G-CSF utilization anticipated in their Phase 2 study, which may hinder the effectiveness of their clinical programs. Additionally, the Inflation Reduction Act of 2022 raises concerns over reduced pricing power in the biopharmaceutical sector, potentially impairing the company's future cash inflows. Furthermore, the expansive nature of C4 Therapeutics' programs aimed at difficult-to-drug opportunities poses substantial risk of regulatory scrutiny, especially in the absence of compelling clinical trial data.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.